文献速递泌尿生殖骨肌MR

扩散加权成像作为评估前列腺癌骨转移治疗反应的生物标志物:一项初步研究

Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.
PubMed 文献 · Radiology · 2016-11-22

这项前瞻性II期临床试验的MR成像子研究纳入21例转移性去势抵抗性前列腺癌患者,在奥拉帕利治疗基线及12周时行全身DWI,发现6例治疗有反应者总扩散体积均下降而非反应者均未下降(P=0.001),中位ADC升高与治疗反应几率增加相关(OR 1.08,95%CI 1.00-1.15,P=0.04)。

要点

  • 全身DWI测得的总扩散体积下降与奥拉帕利治疗反应显著相关(P=0.001)。
  • 中位ADC升高与治疗反应几率增加相关(OR 1.08,95%CI 1.00-1.15,P=0.04)。
  • 总扩散体积变化与PSA及循环肿瘤细胞变化呈正相关(r=0.63和r=0.77)。

核心结论

  • 这项初步研究显示,全身DWI评估的骨转移灶体积下降和中位ADC升高可能可作为mCRPC患者对奥拉帕利治疗反应的指标。

研究设计与样本

  • 一项聚腺苷二磷酸核糖聚合酶抑制剂奥拉帕利治疗mCRPC的II期前瞻性临床试验所纳入的前瞻性MR成像子研究,共21例患者,使用1.5-T MR成像在基线及奥拉帕利给药12周后行全身DWI。

关键影像表现/征象

  • DWI图像上符合骨转移的异常信号区被勾画以得出总扩散体积(tDV),并评估5个靶病灶。
  • 6例对奥拉帕利有反应者总扩散体积均下降,而所有非反应者均未观察到下降,两者差异显著(P=0.001)。
  • 中位ADC升高与治疗反应几率增加相关(OR 1.08,95%CI 1.00-1.15,P=0.04)。
  • 总扩散体积变化与PSA最佳百分比变化及循环肿瘤细胞计数呈正相关(r=0.63[95%CI 0.27-0.83]和r=0.77[95%CI 0.51-0.90])。
  • 评估5个靶病灶时,体积下降与治疗反应相关(体积增加的OR 0.89,95%CI 0.80-0.99,P=0.037)。

诊断标准与关键数值

  • 以总扩散体积(tDV)变化评估治疗反应:6例反应者tDV均下降,非反应者均无下降(P=0.001)。
  • 中位ADC每升高与治疗反应几率增加相关(OR 1.08,95%CI 1.00-1.15,P=0.04)。
  • 5个靶病灶体积增加与治疗反应几率降低相关(OR 0.89,95%CI 0.80-0.99,P=0.037)。

临床应用与阅片要点

  • 作者认为,全身DWI评估的骨转移灶体积下降和中位ADC升高可能可作为mCRPC患者对奥拉帕利治疗反应的指标。

局限性

  • 原文标明为初步研究(pilot study)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To determine the usefulness of whole-body diffusion-weighted imaging (DWI) to assess the response of bone metastases to treatment in patients with metastatic castration-resistant prostate cancer (mCRPC). Materials and Methods A phase II prospective clinical trial of the poly-(adenosine diphosphate-ribose) polymerase inhibitor olaparib in mCRPC included a prospective magnetic resonance (MR) imaging substudy; the study was approved by the institutional research board, and written informed consent was obtained. Whole-body DWI was performed at baseline and after 12 weeks of olaparib administration by using 1.5-T MR imaging. Areas of abnormal signal intensity on DWI images in keeping with bone metastases were delineated to derive total diffusion volume (tDV); five target lesions were also evaluated. Associations of changes in volume of bone metastases and median apparent diffusion coefficient (ADC) with response to treatment were assessed by using the Mann-Whitney test and logistic regression; correlation with prostate-specific antigen level and circulating tumor cell count were assessed by using Spearman correlation (r). Results Twenty-one patients were included. All six responders to olaparib showed a decrease in tDV, while no decrease was observed in all nonresponders; this difference between responders and nonresponders was significant (P = .001). Increases in median ADC were associated with increased odds of response (odds ratio, 1.08; 95% confidence interval [CI]: 1.00, 1.15; P = .04). A positive association was detected between changes in tDV and best percentage change in prostate-specific antigen level and circulating tumor cell count (r = 0.63 [95% CI: 0.27, 0.83] and r = 0.77 [95% CI: 0.51, 0.90], respectively). When assessing five target lesions, decreases in volume were associated with response (odds ratio for volume increase, 0.89; 95% CI: 0.80, 0.99; P = .037). Conclusion This pilot study showed that decreases in volume and increases in median ADC of bone metastases assessed with whole-body DWI can potentially be used as indicators of response to olaparib in mCRPC. Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Perez-Lopez R, Mateo J, Mossop H, et al. Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study. Radiology. 2016. PMID: 27875103. doi:10.1148/radiol.2016160646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。